AstraZeneca PLC and Ardea Biosciences, Inc. Release: A Large, Observational Study of Common Gout Treatment Allopurinol Shows Less Than Half of Patients Reach Recommended Treatment Goal
Published: Oct 28, 2013
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Ardea Biosciences today presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, 6-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol. Results of the LASSO study showed no new safety signals with allopurinol doses of approximately 300mg/day. The study also revealed that at the time of last dose fewer than half (43%) of patients taking allopurinol achieved the target serum uric acid (sUA) level of <6.0 mg/dL, the level recommended by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Results of the LASSO study were presented today at the ACR Annual Meeting in San Diego, CA.
Help employers find you! Check out all the jobs and post your resume.